Nc-RNA 介导的 AZIN1 低表达与肾透明细胞癌的不良预后相关。

Nc-RNA-mediated low expression of AZIN1 correlated with unfavorable prognosis in kidney renal clear cell carcinoma.

机构信息

Department of Hematology, Huadong Hospital Affiliated with Fudan University, Shanghai, China.

Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.

出版信息

Cancer Med. 2024 Aug;13(15):e70105. doi: 10.1002/cam4.70105.

DOI:10.1002/cam4.70105

PMID:39140420

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11322861/

Abstract

OBJECTIVE

Kidney renal clear cell carcinoma (KIRC, ccRCC) is the most common type of renal cancer with high recurrence and mortality. It has long been recognized that Antizyme inhibitor 1 (AZIN1) serves as a pro-oncogenic molecule in multiple cancers. However, the clinicopathological features of AZIN1 in KIRC remain unexplored.

MATERIALS AND METHODS

The Cancer Genome Atlas (TCGA, TIMER, and GEPIA) were employed for pan-cancer expression and survival analysis of AZIN1, indicating the unique anti-tumor role of AZIN1 in KIRC. The expression and clinical characteristics of AZIN1 in KIRC were further proven via Human Protein Atlas and TCGA. single-sample GSEA was employed to investigate the immune infiltration of AZIN1. Then the downstream pathways were illustrated via the LinkedOmics, Metascape, and Cytoscape databases. The possible upper regulating noncoding RNAs (ncRNAs) were analyzed from five programs-TargetScan, StarBase, miRanda, PITA, and miRmap.

RESULTS

AZIN1 is downregulated in KIRC patients. Lower levels of AZIN1 were linked with unfavorable outcomes in KIRC patients. The AZIN1 expression was positively related to immune cell infiltration in KIRC. We also elucidated a possible upstream regulatory ncRNA of AZIN1 in KIRC namely STK4-AS1/AC068338.2-miR-106b-5p-AZIN1 axis as well as the downstream signaling pathways.

CONCLUSION

This study illustrated the unique anti-tumor role of AZIN1 in KIRC and provided potential value for guiding immunotherapy and targeted therapy.

摘要

目的

肾透明细胞癌（KIRC，ccRCC）是最常见的肾癌类型，具有高复发率和高死亡率。长期以来，人们一直认为 Antizyme inhibitor 1（AZIN1）在多种癌症中是一种致癌分子。然而，AZIN1 在 KIRC 中的临床病理特征仍未得到探索。

材料和方法

利用癌症基因组图谱（TCGA、TIMER 和 GEPIA）进行了 pan-cancer 的 AZIN1 表达和生存分析，表明 AZIN1 在 KIRC 中具有独特的抗肿瘤作用。通过 Human Protein Atlas 和 TCGA 进一步证实了 AZIN1 在 KIRC 中的表达和临床特征。单样本 GSEA 用于研究 AZIN1 的免疫浸润。然后通过 LinkedOmics、Metascape 和 Cytoscape 数据库阐明下游途径。从五个程序（TargetScan、StarBase、miRanda、PITA 和 miRmap）分析了可能的上调控非编码 RNA（ncRNA）。

结果

AZIN1 在 KIRC 患者中下调。AZIN1 水平较低与 KIRC 患者的不良预后相关。AZIN1 的表达与 KIRC 中的免疫细胞浸润呈正相关。我们还阐明了 KIRC 中可能的上游调节性 ncRNA，即 STK4-AS1/AC068338.2-miR-106b-5p-AZIN1 轴以及下游信号通路。